Zacks Investment Research upgraded shares of Mersana Therapeutics (NASDAQ:MRSN) from a hold rating to a buy rating in a research report report published on Thursday morning. The brokerage currently has $20.00 price objective on the stock.
According to Zacks, “Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company’s product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States. “
Other equities analysts have also recently issued research reports about the company. HC Wainwright assumed coverage on Mersana Therapeutics in a report on Thursday, February 15th. They set a buy rating for the company. ValuEngine raised Mersana Therapeutics from a strong sell rating to a sell rating in a report on Friday, February 2nd. Finally, JPMorgan Chase & Co. cut Mersana Therapeutics from an overweight rating to a neutral rating and set a $23.00 target price for the company. in a report on Monday, March 19th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. The company currently has an average rating of Hold and an average target price of $24.80.
Institutional investors have recently made changes to their positions in the business. TIAA CREF Investment Management LLC raised its holdings in shares of Mersana Therapeutics by 1,132.7% during the fourth quarter. TIAA CREF Investment Management LLC now owns 8,037 shares of the company’s stock valued at $132,000 after acquiring an additional 7,385 shares during the last quarter. California State Teachers Retirement System acquired a new position in shares of Mersana Therapeutics during the third quarter valued at approximately $142,000. Candriam Luxembourg S.C.A. acquired a new position in shares of Mersana Therapeutics during the fourth quarter valued at approximately $197,000. Bank of New York Mellon Corp acquired a new position in shares of Mersana Therapeutics during the third quarter valued at approximately $231,000. Finally, Goldman Sachs Group Inc. acquired a new position in shares of Mersana Therapeutics during the fourth quarter valued at approximately $247,000. 75.73% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Mersana Therapeutics (MRSN) Stock Rating Upgraded by Zacks Investment Research” was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3299509/mersana-therapeutics-mrsn-stock-rating-upgraded-by-zacks-investment-research.html.
About Mersana Therapeutics
Mersana Therapeutics, Inc is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug’s chances of attacking cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.